COMMUNIQUÉS West-GlobeNewswire

Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines
14/09/2026
Sanofi and Cheplaphar m to create new strategic partnership i n mature medicines Paris , September 14, 2026 . Sanofi and Cheplapharm, a European leader in well-established medicines, today announced their intention to [...]
Communiqué de presse : Sanofi et Cheplapharm créent un nouveau partenariat stratégique autour des médicaments matures
14/09/2026
Sanofi et Cheplapharm créent un nouveau partenariat stratégique autour de s médicaments matures Paris, 14 septembre 2026. Sanofi et Cheplapharm, leader européen des médicaments matures, ont annoncé aujourd'hui leur [...]
Parexel to Lead Sessions at DPHARM 2026 on AI, Talent and the Future of Clinical Operations
14/09/2026
CEO and other Parexel executive leaders will examine enterprise AI adoption, future workforce readiness and patient-first drug development RALEIGH, N.C., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Parexel, a leading global [...]
Bionano Announces Three New Peer-Reviewed Studies Demonstrate Clinical Value of Bionano's Optical Genome Mapping Across Myelodysplastic Syndromes and Acute Myeloid Leukemia
14/09/2026
Independent research teams at MD Anderson Cancer Center, the University of Oulu, and the Josep Carreras Leukaemia Research Institute report that optical genome mapping (OGM) uncovers clinically significant genomic [...]
New Cardiovascular Device Approved in Japan: Elixir Medical Announces Regulatory Approval of DynamX® Coronary Bioadaptor System
14/09/2026
MILPITAS, Calif. and TOKYO , Sept. 14, 2026 (GLOBE NEWSWIRE) -- New Cardiovascular Device Approved in Japan: Elixir Medical Announces Regulatory Approval of DynamX® Coronary Bioadaptor System MILPITAS, Calif. and TOKYO [...]
Coultreon Biopharma Appoints Nate Massari as Chief Business Officer
14/09/2026
Nate Massari’s business development and commercialization expertise in Immunology & Inflammation (I&I), particularly in ulcerative colitis and Crohn’s disease, will support the advancement of Coultreon's first- [...]
Unlocking the Growth - Invitation to BioPorto’s investor meeting on Oct 7
14/09/2026
September 14, 2026 News release Unlocking the Growth - Invitation to BioPorto’s investor meeting on October 7 As BioPorto continues to advance its commercial strategy and capitalize on emerging clinical opportunities, [...]
Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil
14/09/2026
Published Phase 1 data in Sexual Medicine strengthen the scientific foundation for Daré Bioscience’s proprietary topical Sildenafil Cream, 3.6% At the 71 mg topical dose, mean maximum plasma concentration of sildenafil [...]
Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial
14/09/2026
- Enrollment of 239 Patients Meets Upper End of Planned Enrollment Target Range - - Topline Data Expected in November 2026 - ATLANTA, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“ [...]
Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings
14/09/2026
Presentations examine where Annamycin concentrates in the body, how it targets topoisomerase II, and its antitumor activity in pancreatic cancer HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. ( [...]
Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
14/09/2026
RMAT Designation Supported by Positive Interim Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 which Demonstrated Reduced Arrhythmia Burden Additional Data and Updates on Regulatory Discussions Anticipated in 4Q [...]
Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition
14/09/2026
Initial Advance of $2.5 Million to Realbotix LLC to Support Growth and Working Capital; Non-Interest Bearing Facility Is Automatically Cancelled and Discharged in Full Upon Closing of Pending Acquisition CINCINNATI, [...]
Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote “FOR” All Six of Anavex’s Highly Qualified Director Nominees
14/09/2026
ISS Recognizes There is No Case for Change Anavex Urges Stockholders to Follow ISS’ Recommendation and Vote “FOR” ALL Six Director Nominees on the WHITE Proxy Card Today NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- [...]
Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement
14/09/2026
Under the terms of the Amendment, all disputed issues are resolved SAN DIEGO and NERVIANO, Italy, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ: CRDF) ("Cardiff") and Nerviano Medical Sciences S.r.l [...]
GATC Health Joins Critical Path Institute’s New Approach Methodologies Developer Coalition to Advance AI-Enabled Regulatory Science
14/09/2026
GATC to contribute AI-native, in silico drug discovery and predictive modeling expertise and insights to collaborative effort advancing the validation, qualification and adoption of human-relevant drug development tools [...]
Tris Pharma Introduces New 30-Count Bottle Size for QuilliChew ER® (methylphenidate HCl) Extended-Release Chewable Tablets for Attention Deficit Hyperactivity Disorder (ADHD)
14/09/2026
A new, smaller 30-count bottle of the once-daily chewable methylphenidate offers pharmacists easier stocking and patients a 30-day supply at common dosing levels, available now as families navigate the back-to-school [...]
Nord Fascia Launches Personalized Fascia Release and Mobility App
14/09/2026
Nord Fascia App Turns a Short Quiz Into a Daily Fascia Release and Stretching Routine NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Nord Fascia has launched a personalized wellness app built around fascia release, [...]
Santa Ana Bio Announces First Subjects Dosed in Phase 1 Study of SAB01 to Treat Autoimmune Inflammatory Diseases
14/09/2026
First-in-class bispecific antibody designed for mast cell elimination without the safety issues associated with current KIT therapeutics Phase 1 single ascending dose study to evaluate the safety, pharmacokinetics, and [...]
Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy
14/09/2026
PARSIPPANY, N.J. and TEL AVIV, Israel, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), a global biopharmaceutical company, today announced that its ordinary shares will [...]

Pages